Researchers at Shandong University in China have modified the probiotic bacterium Escherichia coli Nissle 1917 to produce and deliver the FDA-approved anticancer drug Romidepsin (FK228) directly inside tumors. The engineered bacteria successfully accumulated within tumors in mice and released the drug on site, combining bacterial tumor colonization with the drug's inherent anticancer properties for a dual-action attack.
The findings, published March 17 in PLOS Biology, demonstrate a targeted delivery system that could make cancer treatments more effective while reducing side effects on healthy tissue. Lead researcher Tianyu Jiang noted the approach shows "great promise" by leveraging engineered probiotics as bacteria-assisted, tumor-targeted therapy platforms.
The technique has not yet been tested in humans. Future studies will need to examine safety profiles and strategies for safely removing the bacteria after treatment before clinical trials can begin.
